---
title: "Aptevo Therap | 8-K: FY2026 Q2 Revenue: USD 1.5 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295932741.md"
datetime: "2026-08-14T12:12:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295932741.md)
  - [en](https://longbridge.com/en/news/295932741.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295932741.md)
generator: "portal-rs"
---

# Aptevo Therap | 8-K: FY2026 Q2 Revenue: USD 1.5 M

Revenue: As of FY2026 Q2, the actual value is USD 1.5 M.

#### Financial Position

Aptevo Therapeutics Inc. reported cash and cash equivalents totaling $9.8 million as of June 30, 2026.

#### Capital Activities

During the second quarter of 2026, Aptevo Therapeutics Inc. raised $0.6 million under its Standby Equity Purchase Agreements (SEPAs) with Yorkville. The company also secured a $1.5 million non-dilutive research grant from the Andy Hill Cancer Research Endowment (CARE) Fund to support IND-enabling work for APVO451. Niowave made an at-the-market equity investment in Aptevo Therapeutics Inc. at closing, representing an initial 7.9% ownership position, with the potential to build up to 19.99%.

#### Operational Metrics (Clinical Development - Mipletamig)

In the Phase 1b/2 RAINIER trial for mipletamig, Aptevo Therapeutics Inc. demonstrated an 87% clinical benefit rate and an 81% remission rate across 31 evaluable unfit frontline AML patients. Among patients who achieved CR/CRi, 55% had blast reductions reaching the measurable residual disease-negative level (MRD neg). Additionally, 36% of patients with remissions had the TP53 genetic mutation. Six patients treated to date have proceeded to allogeneic stem cell transplant.

#### Outlook / Guidance

Aptevo Therapeutics Inc. anticipates completing dose optimization for mipletamig by year-end 2026 and expects a Phase 2 regulatory interaction in the first quarter of 2027. For APVO451, development candidate selection is targeted by year-end 2026, with IND-enabling studies planned for the first quarter of 2027. The company has also entered a 50⁄50 collaboration with Niowave to develop up to three radiopharmaceutical oncology programs, expanding its development strategy.

### Related Stocks

- [APVO.US](https://longbridge.com/en/quote/APVO.US.md)

## Related News & Research

- [Aptevo Therapeutics held annual shareholder meeting](https://longbridge.com/en/news/296648533.md)
- [Aptevo Therapeutics announces special shareholder meeting](https://longbridge.com/en/news/296649507.md)
- [Home Depot declares quarterly dividend of $2.33 a share](https://longbridge.com/en/news/296531433.md)
- [Skye Bio amends 8-K to set Aug. 24 effective date for reverse stock split](https://longbridge.com/en/news/296471274.md)
- [Vital Farms amends 8-K to add missing Item 5.03 in EDGAR header](https://longbridge.com/en/news/296122466.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**